Summary
Thirty hypertensive outpatients were treated with moxonidine for 4 weeks in an intraindividual comparison study. After a wash-out period of at least 2 weeks the same patients were given prazosin for 4 weeks. The initial daily doses were 0.2 mg moxonidine and 1 mg prazosin. The antihypertensive dose was titrated individually until the diastolic blood pressure (BP) fell below 95 mm Hg.
Within 3 days of dose titration, a mean dose of 0.37 mg moxonidine produced a significant decrease in BP from a mean of 184/100 to 155/90 mm Hg, while in prazosin treated patients 5 to 8 days were necessary to reduce the BP from 180/100 to 149/89 mm Hg; the mean prazosin dose was 2.8 mg. In addition to the lower dose of moxonidine compared to prazosin, it was found that in 67% of patients moxonidine was given once daily whilst prazosin was administered three-time daily in 73%.
Within the first week of moxonidine treatment 14/30 patients experienced dryness of the mouth, but it was so mild that the patients did not want to discontinue the trial. In contrast, 3/30 patients discontinued therapy with prazosin because of side effects. The most frequent adverse effects of prazosin were orthostatic dysregulation in 6 patients, pain in the chest in 5, giddiness and tachycardia in 4 and nervousness in 3 patients; no patient had these complaints whilst on moxonidine.
In intraindividual comparisons with moxonidine, efficacy, tolerance and the well-being of the patients were significantly better than when on prazosin.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Armah B, Stenzel W (1981) BE-5895, a new clonidine-type antihypertensive aminopyrimidine derivative. Naunyn Schmiedeberg's Arch Pharmacol 316 [Suppl]: R42
Bergerhausen J (1985) Moxonidine (BE 5895) a full agonist at human platelet α2-adrenoceptors. Naunyn Schmiedeberg's Arch Pharmacol 329 [Suppl]: R80
Plänitz V, Hoffmann K (1983) First clinical data on moxonidine·HCl for treatment of mild to moderate hypertension. Naunyn Schmiedeberg's Arch Pharmacol 324 [Suppl]: R79
Frisk-Holmberg M, Plänitz V (1985) Selective alpha-adrenoceptor agonists in arterial essential hypertension. Clinical experience with moxonidine. Filed for publication
Plänitz V (1984) Crossover comparison of moxonidine and clonidine in mild moderate hypertension. Eur J Clin Pharmacol 27: 147–152
Plänitz V, Stenzel W, Hoffmann K (1985) Double-blind crossover comparison of moxonidine and clonidine-HCl. Herz/Kreislauf 17: 420–25
Cambridge D, Davey MJ, Massingham R (1977) The pharmacology of antihypertensive drugs with special reference to vasodilators, α-adrenergic blocking agents and prazosin. Med J Austr 2 [Specl. Suppl]: 2–6
Bolli P, Wood AJ, Simpson FO (1976) Effects of prazosin in patients with hypertension. Clin Pharmacol Ther 20: 138–141
Stokes GS, Gain JM, Mahony JF, Raftos J, Stewart JH (1977) Long-term use of prazosin in combination or alone for treating hypertension. Med J Austr 2 [Specl. Suppl]: 13–16
Seideman P, Grahnén A, Haglund K, Lindström B, von Bahr C (1981) Prazosin dynamics in hypertension: Relationship to plasma concentration. Clin Pharmacol Ther 30: 447–454
Guthrie GP, Kotchen TA (1983) Effects of prazosin and clonidine on sympathetic baroreflex function in patients with essential hypertension. J Clin Pharmacol 23: 348–354
Hubbell FA, Weber MA, Drayer JIM, Rose DE (1983) Combined central and peripheral sympathetic blockade: Absence of additive antihypertensive effects. Am J Med Sci 285: 18–25
Hubbell FA, Weber MA, Drayer JIM, Rose DE (1984) Comparative antihypertensive and endocrinologic effects of clonidine and prazosin in patients with essential hypertension. South Med J 77: 1264–1268
Deutsche Liga zur Bekämpfung des hohen Blutdrucks (1984) Empfehlungen zur Hochdruckbehandlung in der Praxis und zur Behandlung hypertensiver Notfälle der Deutschen Liga zur Bekämpfung des hohen Blutdrucks e. V., 6. Auflage, Im Neuenheimer Feld 366, Heidelberg
Fauchald P, Helgeland A (1979) Treatment of hypertension with prazosin. An open study in general practice. Acta Med Scand 205 [Suppl 625]: 141–142
Rosenthal J, Gabriel H (1984) 24-Stunden-Blutdruckprofile unter Behandlung mit Prazosin. Medwelt 35: 1534–1536
Seideman P, Grahnén A, Haglund K, Lindström B, von Bahr C (1982) Prazosin first dose phenomenon during combined treatment with a β-adrenoceptor blocker in hypertensive patients. Br J Clin Pharmacol 13: 865–870
Grahnén A, Seideman P, Lindström B, Haglund K, von Bahr C (1981) Prazosin kinetics in hypertension. Clin Pharmacol Ther 30: 439–446
Pitkäjärvi T, Kyöstilä S, Kontro J, Mattila MJ (1977) Antihypertensive drug combinations: Prazosin, hydrochlorothiazide and clonidine. Ann Clin Res 9: 296–300
Colucci WS (1983) Alpha-Rezeptorenblockade mit Prazosin. Therapiewoche 33: 1894–1913
Borghi C, Pallavini G, Comi D, Grillo G, Lombardo M, Mantero O, Minetti L, Selvini A, Suppa G (1984) Comparison of three different methods of monitoring unwanted effect during antihypertensive therapy. Int J Clin Pharmacol Ther Toxicol 22: 324–328
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Plänitz, V. Intraindividual comparison of moxonidine and prazosin in hypertensive patients. Eur J Clin Pharmacol 29, 645–650 (1986). https://doi.org/10.1007/BF00615953
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00615953